Embody Review

Who actually runs it

Embody is a trading name of Modern Metabolic Medicine, Inc., registered at 1811 Silverside Rd Ste 260, Wilmington, Delaware. The same entity also trades as SnagRx and RodeoMeds — worth knowing, because reviews of those brands reflect on the same operator. Prescribing is handled by clinicians in the OpenLoop Health network, and Embody names four US 503A compounding pharmacies: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy and Triad Rx. Naming the pharmacies is genuinely above average for this category. The site also displays a LegitScript certification seal in its footer; we were not able to independently confirm the listing through LegitScript's public lookup on the date we checked.

What customers say

Embody's marketing page advertises "(4.8) Excellent! Over 125,000+ happy customers". Its Trustpilot profile is a good deal more mixed, sitting in the region of 3.6–3.7 across several thousand reviews, with roughly 56% five-star and around 23% one-star. That barbell shape — lots of delighted customers, a large minority of angry ones — is typical of a fast-growing telehealth brand whose operations have not caught up with its marketing. Recurring complaint themes are month-two pricing, consultations that did not happen as scheduled, and difficulty reaching support. Treat the 4.8 figure as a marketing claim, not an independent score.

Claims that do not hold up

Embody's landing page states that patients "report an average loss of 1.5% of their body weight per week" and calls the programme "the proven way to lose 15% of your body weight fast". Sustained at 1.5% per week, a 200lb person would lose their entire body weight inside a year and a half. The same page elsewhere says 12-week loss "can be as high as 10%", which is a different and far more plausible claim — the two cannot both be right. For reference, the STEP 1 trial of semaglutide 2.4 mg recorded a mean 14.9% loss at 68 weeks, and SURMOUNT-1 recorded 20.9% for tirzepatide 15 mg at 72 weeks. Those are the approved branded drugs studied over well more than a year. Marketing of this type is precisely what drew FDA warning letters to dozens of Embody's competitors in 2026.

What to check before you buy

• •Get your renewal price in writing — the one-month plan lists a $299.00 regular price behind the $79.00 promo
• •Read the refund policy: once medication is ordered, refunds stop, and cancellation needs 72 hours' notice
• •Think hard before prepaying 6 or 12 months to a company with an F for unanswered complaints
• •Ask which of the four named pharmacies will fill your prescription, and whether it is 503A or 503B
• •Ask what clinical basis supports compounding in your case, now that neither drug is in shortage
• •If you are considering the gum, ask for absorption data before paying three times the injection price

How much does Embody actually cost?

It depends almost entirely on how long a plan you commit to, and the answer is genuinely cheap if you prepay. Checked on 7 August 2026, Embody's own product pages list compounded semaglutide injections at $79.00 for one month, $228.00 for three months ($76/month), $438.00 for six months ($73/month) and $828.00 for twelve months ($69/month). Compounded tirzepatide injections are advertised from $119–$129/month depending on which landing page you arrive through. The gum formats are much more expensive: $229.00 for a month of semaglutide gum and $329.00 for a month of tirzepatide gum. The critical detail is on the one-month page, which shows $79.00 as a sale price against a regular price of $299.00. Confirm in writing what your second month will bill at before you pay anything.

Why do people say the price jumps in month two?

Because Embody's own store lists a $299.00 regular price for a one-month supply of compounded semaglutide, with the $79.00 figure presented as a promotional sale price under a 'Summer Start Promo' banner. Month-two price shock is the most consistent theme in negative reviews of the brand. We could not verify from the public site exactly which customers renew at which rate, and we are not going to state a renewal price we cannot confirm — but the gap between the advertised and regular prices is documented on Embody's own product page, and it is $220. Ask support to confirm your renewal price in writing before your first billing date.

Is Embody legitimate?

It is a real, operating telehealth business rather than a fake pharmacy — but it is young and its service record is poor. Embody is a trading name of Modern Metabolic Medicine, Inc., registered at 1811 Silverside Rd Ste 260, Wilmington, Delaware, which also trades as SnagRx and RodeoMeds. Prescribing runs through the OpenLoop Health clinician network and it names four US compounding pharmacies. The site displays a LegitScript certification seal. Against that: the BBB rates the company F, explicitly for failure to respond to 17 complaints, and lists the business start date as 19 December 2025. We also found no FDA warning letter against it, which is a genuine point in its favour given the FDA wrote to 55 telehealth companies over compounded GLP-1 marketing during 2026.

What does the money-back guarantee actually cover?

Considerably less than the marketing implies. Embody's landing page offers a 'patient satisfaction guarantee' and says that if you are unhappy it will 'make it right'. The published refund policy is narrower: you can be refunded for your current billing cycle 'only if, at the time of the request or cancellation, your medication has not been ordered.' Once the pharmacy has the order, federal law generally prohibits returning dispensed prescription medication, so no refund is available. Cancellation also requires 72 hours' notice before your billing date. You are fully refunded if a clinician declines to prescribe. In practice this protects you before dispensing and not after — which matters a great deal if you have prepaid $828 for a year.

Does Embody offer brand-name Ozempic, Wegovy, Mounjaro or Zepbound?

No. Everything Embody dispenses is compounded. Compounded medications are prepared by licensed compounding pharmacies for patient-specific prescriptions, are not FDA-approved, and are not evaluated by the FDA for safety, effectiveness or quality. They share an active ingredient with the branded products but are not equivalent to them. Embody does not bill insurance either, so if you want an FDA-approved product or want to use coverage, look at the providers on this site that offer insurance navigation instead.

Does the GLP-1 gum work as well as the injection?

Nobody can tell you that, and you should be wary of anyone who says otherwise. Semaglutide and tirzepatide are peptides, which are poorly absorbed by mouth — the one FDA-approved oral semaglutide product, Rybelsus, requires a specific absorption enhancer and strict dosing conditions to achieve useful blood levels. Embody's gum is a compounded formulation, and its own product page states that compounded medications 'are not evaluated or approved by the FDA for safety or effectiveness.' We found no published bioavailability data for it. It also costs $229–$329 per month against $69–$129 for the injections. If needles are genuinely the barrier for you it may be worth discussing with the clinician, but you are paying substantially more for a delivery route with no public evidence behind it.

How much weight will I lose?

This review cannot tell you that, and neither can Embody. For context on what the underlying molecules have achieved in trials of the FDA-approved branded products: in the STEP 1 trial, adults with overweight or obesity without diabetes taking semaglutide 2.4 mg weekly alongside lifestyle intervention lost a mean of 14.9% of body weight at 68 weeks, versus 2.4% on placebo (Wilding et al., New England Journal of Medicine, 2021). In SURMOUNT-1, tirzepatide 15 mg produced a mean 20.9% reduction at 72 weeks versus 3.1% on placebo. Two caveats matter. Those trials studied the approved branded drugs, not compounded copies, which have not been through equivalent trials. And both took well over a year. Embody's landing page claim that patients 'report an average loss of 1.5% of their body weight per week' is not supported by that literature and does not even agree with the same page's statement that 12-week loss 'can be as high as 10%'.

Who should not use these medications?

GLP-1 receptor agonists are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in people who have had a serious allergic reaction to the medication. They should not be used in pregnancy, while trying to conceive, or while breastfeeding. Embody's own safety page also flags a history of severe gastrointestinal disease. In rodent studies these drugs caused thyroid tumours; whether that translates to humans is not known. Common side effects are nausea, constipation, vomiting, diarrhoea, abdominal pain, headache and fatigue, usually worst while titrating up. Serious risks include pancreatitis, gallbladder disease and kidney injury. Discuss your own history with a licensed clinician — this page is information, not medical advice.

Where is Embody available?

Embody states it serves all US states except Louisiana, and that in Nebraska services are limited to patients aged 19 or over. It is a United States service only. State-by-state telehealth rules change, so confirm your own state during intake.